Cimetidine 800 mg given at night is as effective as 400 mg twice daily; the single dose regimen may improve patient compliance, thus facilitating treatment.
laryngeal nerves. After the operation she found that her register had fallen to that of a lyric soprano. Her voice had become coarse, and critics wrote that "the amazing voice is gone forever, instead of cream velvet there is a sad quivering ghost." '16 The incidence of voice changes after thyroidectomy in our retrospective series probably underestimates the true incidence as only 78% of the patients were assessed clinically; but the vulnerability of the many components of voice production is emphasised. The external laryngeal nerves need to be as precisely identified as the recurrent laryngeal nerve, and to be protected against diathermy burns and ligation. The cricothyroid muscle and adjacent small joints should be handled gently, and the strap muscles should not be routinely sacrificed.
Voice assessment should be as much a part of follow up after thyroidectomy as are measurements of serum calcium concentrations. Laryngeal examination before and after operation by an otolaryngologist and speech therapist is advisable and should include indirect laryngoscopy and objective voice assessment. The Visipitch oscilloscope offers a sensitive measurement of voice function that will help select those requiring early intensive speech therapy.
We thank Ms Caroline Dore for statistical advice.
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M M PLATTS, E ANASTASSIADES, S SHERIFF, S SMITH, D C C BARTOLO Abstract
To investigate the cause of clinically detectable splenomegaly, which is common in patients receiving regular haemodialysis, splenic volume was assessed by isotopic scanning using intravenously injected technetium-99m microspheres in 34 controls and 149 patients with chronic renal failure. Of the patients, 16 had never received dialysis, 10 were undergoing continuous peritoneal dialysis, 94 were undergoing regular haemodialysis, and 29 had undergone successful renal transplantation more than nine months previously. Mean splenic volume was increased only in the patients who were receiving haemodialysis. Splenic enlargement was probably not due to iron overload as it occurred in all patients who had received haemodialysis, 14 of whom had not received intravenous iron. No patient had had hepatitis.
Splenic enlargement was probably related to the process of haemodialysis itself and may have been due either to red cell damage produced by haemodialysis or to an immunological reaction induced by a component of haemodialysis, possibly ethylene oxide.
Introduction During routine examination we are able to feel the spleen in many of our patients receiving regular haemodialysis. Others have observed that spleens removed from such patients for the treatment of refractory anaemia,1-4 in preparation for renal transplant,5 or at postmortem examination6 are usually enlarged. We know, however, of no survey of the prevalence of splenomegaly in patients with chronic renal failure. We therefore measured splenic volume by radioisotope imaging in patients with chronic renal failure who had not received dialysis, were being treated by continuous ambulatory peritoneal dialysis or regular haemodialysis, or had undergone successful renal transplantation and compared these volumes with those found in patients with normal renal function.
Subjects and methods
Between 1979 two measurements in the individual patients, expressed as a proportion of the weighed spleens, was 17-9%. years' haemodialysis. In one woman (case 5) splenic volume was 657 ml after three years' haemodialysis and 398 ml four months after treatment had been changed to continuous ambulatory peritoneal dialysis. The remaining 13 patients to have spleen volume measured twice had a mean splenic volume of 395 ml while they were receiving intravenous iron in addition to haemodialysis. Later, when no intravenous iron had been given for between 14 and 39 months' haemodialysis, the mean splenic volume was unchanged at 410 ml (p > 0-1). During the same interval the mean serum ferritin concentration of these patients decreased from 2434 to 1624 ,ugil, but this change was not significant (p > 0 1).
The mean (SD) serum ferritin concentration was 2068 (419) ,ug/l in the patients undergoing haemodialysis who had received intravenous iron but was not above our normal range (115-250 ,ug/l) in the other groups of patients.
Computer analysis showed no correlation between splenic volume and the time since transplantation or duration of haemodialysis after the first nine months, the cumulative dose of intravenous iron, the serum ferritin concentration, or the number of blood transfusions received. There was no difference between the splenic volumes of those patients undergoing haemodialysis who had used water for dialysis containing more than 1-85 /Lmol/l (5 mg/100 ml) aluminium and those patients who had always used water containing less aluminium than this.
Discussion
The weight of the normal adult human spleen post mortem varies considerably but averages about 100 g.8-10 Spleens weigh less in females and older people. Obviously, splenic volumes measured isotopically in normal subjects have not been confirmed by direct weighing, but our correlation between direct measurement and isotopic scanning in patients is reasonable as is that found by other authors.I' 12 Larsen et al derived a formula for calculating the splenic volume from the isotopically measured posterior length of the spleen. Using this formula the average volume of the spleen in their 26 normal young adult subjects would have been 173 ml. This agrees reasonably well with the mean value obtained in our control subjects (218 ml). Not surprisingly, in vivo values of splenic volume in unstressed subjects are higher than splenic weights after splenectomy or at postmortem examination, when exsanguination or agonal contraction commonly reduces the volume.
Even if our measurements for splenic volume do not reflect the precise weight, the principle finding that splenic volume is significantly greater in subjects undergoing haemodialysis than in patients with renal failure treated by other methods is not affected. It is well recognised that almost all patients with chronic uraemia are anaemic and that the survival of their red cells may be diminished,"" yet splenomegaly is characteristic only of the groups undergoing haemodialysis. Others who have noticed this splenomegaly have attributed it variously to venous congestion due to fluid overload,7" viral hepatitis, cirrhosis or stimulation of the immune system by chronic bacterial or viral infections,'6 or the presence of foreign particles in the pulp."' Our findings do not support these hypotheses.
Our patients undergoing haemodialysis were, in general, cooperative with their restricted fluid intake, and gross fluid overload was rare and certainly no more common than in patients with uraemia who had not received dialysis or those treated by continuous peritoneal dialysis. None of our patients had had viral hepatitis during the course of treatment with dialysis. Infections did not appear to be more corrmon in patients undergoing haemodialysis than in the other groups with renal failure, and foreign body inclusions such as fragments of silicone were not seen in any of 40 spleens removed from patients who had received haemodialysis in our unit. '8 At first we thought that the splenomegaly in patients undergoing haemodialysis was due to the iron overload in those who had received intravenous iron. Spleens removed from patients who had received intravenous iron all showed heavy iron staining,"' and spleens removed from patients who had not received intravenous iron contained little or no iron. As there was no difference, however, in mean splenic weights between the two groups receiving haemodialysis the splenic enlargement cannot be attributed to iron overload. Differences in the sex and age distribution in the different groups were insufficient to account for the differences in spleen size. Some reduction in spleen size in the transplant group may possibly have been due to administration of corticosteroids or to radiotherapy.
We conclude that the splenomegaly in our patients receiving regular haemodialysis was due to the process of haemodialysis itself. The spleen may enlarge as a result of removal of erythrocytes damaged mechanically in the haemodialysis circuit or chemically by chloramines, bacterial toxins, or other contaminants in the dialysate. We did not find that excessive amounts of aluminium in the dialysate affected splenic volume. Splenic enlargement may be a response to an antigen encountered only during haemodialysis. Recently we have observed anaphylactic reactions in patients treated by regular dialysis. Epidemiological investigation has suggested that these patients are sensitive to ethylene oxide, with which their dialysers are sterilised. 19 In a group of seven, six had an IgE specific for ethylene oxide treated albumin in their serum (to be published).
Appendix
Calculation of splenic volume-Consider the image of the spleen digitised into pixels. If the distribution of radioactivity in the spleen is uniform (a reasonable assumption in patients with renal failure) the value of a single pixel depends primarily on the thickness of the organ below the pixel. If the thickness is d, the attenuation coefficient for the radiation detected u, the pixel area a, the specific activity in the spleen A, and the sensitivity of the camera S, the counts measured by a single pixel are C = SAa(1-e-ud)/u. C is not linearly proportional to d but monotonically related to it. If S, A, a, u, and C are known, d may be computed. Usually only C, a, and u are known. The maximum thickness of the spleen, d max, however, corresponds to the maximum counts in the image, C max. Using these values we can write C/C max = (1-e -ud)/(l eudmax) which enables d to be calculated for any value of C. Thus an image of splenic thickness may be obtained, and, by adding these individual values multiplied by pixel area, an estimate of organ volume may be obtained. The summation is taken over pixels with activity greater than 25% of the maximum. The thickness of an organ should be estimated from a view at right angles to the one used to estimate the volume. For the spleen the thickness is measured from a left lateral view and the volume from a posterior view.
Comparison of cimetidine 800 mg once daily and 400 mg twice daily in acute duodenal ulceration LUCIO CAPURSO, PIER ROBERTO DAL MONTE, FRANCESCO MAZZEO, GIORGIO MENARDO, ANTONIO MORETTINI, ALFREDO SAGGIORO, GIOVANNI TAFNER Abstract A double blind trial was conducted in seven centres to evaluate the safety and efficacy of cimetidine 800 mg given at night compared with 400 mg given at breakfast and at bedtime. Altogether 197 patients with active duodenal ulcer confirmed by endoscopy entered the study, of whom 187 were eligible for analysis. After four weeks' treatment the ulcer was healed in 76 of 91 patients (84%) receiving the once daily regimen and in 65 of the 96 patients (68%) receiving the twice daily regimen (p <0 05). Both dosage regimens were equally effective in reducing ulcer pain and consumption of antacids. Pain relief was considerable within the first two weeks, and most of the patients were free of symptoms by the end of treatment. No patients were withdrawn because of adverse events as these were few and mild, consistent with the proved safety profile of cimetidine.
Introduction
Evidence is growing that nocturnal hypersecretion of acid is an important factor in the pathogenesis of duodenal ulcer, as originally proposed by Dragstedt and Owens.' Pharmacological studies performed by Gledhill et al comparing a single 800 mg dose of cimetidine given at night with 400 mg given twice daily showed that both dosage regimens were equally effective in reducing mean 24 hour intragastric acidity and that nocturnal secretion of acid was significantly better controlled with cimetidine 800 mg at night than with the twice daily regimen.2 On the basis of these findings they suggested that a single night time dose should be evaluated in a clinical trial. Results of an open randomised clinical trial of cimetidine 800 mg were recently published and showed that healing rates and duration of treatment were not different when cimetidine was given as 800 mg once daily or as 400 mg twice daily.3
The purpose of our multicentre study was to investigate in a double blind fashion the safety and efficacy of cimetidine 800 mg once daily compared with 400 mg twice daily in patients with duodenal ulceration.
Patients and methods
Seven centres particip?;te-;n this study. Patients with duodenal ulcer confirmed endoscopically within the previous four days were randomly allocated by a double dummy technique to receive cimetidine twice daily (one 400 mg tablet at breakfast and one 400 mg tablet at bedtime) or once daily (two 400 mg tablets at bedtime). Treatment was continued for four weeks, at the end of which patients were re-examined endoscopically. During the treatment period all other drugs for peptic ulceration were stopped except for a specific antacid to be taken solely for relief of pain not controlled by cimetidine. After two and four weeks the paticnts were examined clinically and interviewed about the occurrence of adverse reactions; details were obtained on ulcer pain and consumption of antacids, which they had previously recorded on diary cards.
Results
At a previously determined date 197 patients were eligible for entry into the stu-dy; of these, 187 were eligible for analysis after
